期刊文献+

定心胶囊对房颤大鼠血清D-二聚体的影响 被引量:6

Experimental Study on Effective Therapy of D-D for Dingxin Capsule to Rats of Atrial Fibrillation
原文传递
导出
摘要 目的:通过探讨定心胶囊对房颤大鼠血清D-二聚体含量的影响,揭示益气养阴活血中药预防和治疗房颤的作用机制。方法:选用体重在200~250 g的健康雄性Wistar大鼠,建立慢性房颤的动物模型。将造模成功的30只大鼠随机分为3组:模型组、定心胶囊治疗组(16.2 g·kg-1.d-1)和维拉帕米对照组(4.5 mg·kg-1.d-1),另设一组正常对照组。用药4周后,观察各组房颤大鼠血清D-二聚体的变化。结果:大鼠房颤模型组与正常对照组比较,血清D-二聚体的含量明显增加(P<0.05)。定心胶囊治疗组和维拉帕米对照组与模型组比较,可以明显地降低血清中D-二聚体的含量(P<0.05)。定心胶囊治疗组与维拉帕米对照组对房颤大鼠血清中D-二聚体的改善程度相比前者优于后者(P<0.05),有统计学意义。结论:定心胶囊能够明显降低房颤大鼠血清D-二聚体的水平,是防治房颤的有效药物。 Objective:The aim of this study is to develop the effective therapy on Dingxin capsule for D-dimer(D-D)of atrial fibrillation.To reveal the mechanism of Chinese medicine with the effects of nourishing Qi and Yin and activating blood in the prevention and treatment of Atrial Fibrillation(AF).Method:Forty rats were randomized to 4 groups:normal group,model group,Dingxin capsule curatio group,verpamil intervention group.The level of D-D of AF rats were measured.Result:With the comparison of treating group and model group,the level of D-D in treating group lowed obviously(P0.05).Both of them had statistic significance.Both Dingxin capsule group and Verpamil intervention group could low the level of D-D,but Dingxin capsule group is better.Conclusion:Dingxin capsule could correct the level of D-D in AF rats.D-D played important role in the pathogenesis of AF.
作者 王祺 张艳
出处 《中国实验方剂学杂志》 CAS 北大核心 2011年第11期243-245,共3页 Chinese Journal of Experimental Traditional Medical Formulae
基金 辽宁省教育厅课题(202153332)
关键词 定心胶囊 房颤 D-二聚体 Dingxin capsule atrial fibrillation D-dimer
  • 相关文献

参考文献6

二级参考文献15

  • 1成都中医学院.中药学[M].上海:上海科学技术出版社,1982.285.
  • 2Wilensky R, Jung S. Thromboembolism in patients with decreased left ventrionlar function[J]. J Cardiovasc Risk, 1995, 2(2) : 91-96.
  • 3Rupak Mukherjee, Amanda R Hemon, Lowry AS, et al. Selective induction of matrix metallo proteinases and tissue inhibitor of metalloproteinases in atrial and ventricularmyocardium in patients with atrial fibrillation[J]. Am Cardiol, 2006,97: 532-537.
  • 4Xu J, Cui G, Esmailian F, et al. Atrial extracellularmatrix remodeling and the maintenance of atrial fibrillation[J]. Circulation, 2004,109: 363-368.
  • 5BeaudeuxJL, Giral P, Bruckert E, et al. Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives[J]. Clin Cherm Lab Med, 2004,42(2): 121-131.
  • 6[2]Minamino T,Kitakaze M,Asanuma H,et al.Platelet activation in patients with atrial fibrillation[J].Am J Cardiol,1999,83(1):194-198
  • 7[3]Tetsuo M,Masafumi K.Increased expression of P-selection on platelets is arisk factor for silent cerebral infraction in patient with atrial fibrillation[J].Circulation,1998,98:1721-1727
  • 8[3]Rupak Mukherjee Php,Amanda R Hemon BS,Abigails,et al.Selective Induction of Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Atrial and Ventricular Myocardium in Patients With Atvial Fibrillation[J].Am/Cardiol,2006,97:532-537
  • 9[4]Xu J,Cui G,Esmailian F,et al.Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation[J].Circulation,2004,109:363-368
  • 10[6]Beaudeux JL,Giral P,Bruckert E,et al.Matrix metalloproteinases,inflammation and atherosclerosis:therapeutic perspectives[J].Clin Cherm Lab Med,2004,42(2):12l-131

共引文献66

同被引文献70

引证文献6

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部